MSK-ACCESS® powered with SOPHiA DDM™: In-house performance results

The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. Through an in-depth exploration of our internal verification study and insights from Privileged Access Program (PAP) sites, we will showcase how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges, delivering high concordance with single-site testing. 

Decentralization of a sophisticated genomic assay like MSK-ACCESS® presents significant challenges, from ensuring analytical accuracy to managing variability across multiple sites. The SOPHiA DDM™ Platform, with its advanced analytics, noise reduction technology, and streamlined wet-lab workflows, is designed to overcome these hurdles. Our rigorous internal verification study has demonstrated excellent performance, confirming that the decentralized version of MSK-ACCESS® maintains a high level of concordance with the original single-site test. 

Beyond internal validation, real-world insights from six PAP sites further reinforce these findings, demonstrating robust performance across diverse laboratory environments. This success not only validates our decentralized solution but also strengthens our commitment to continuously refining our variant calling algorithms through community-driven data insights. 

Join us to discover how the SOPHiA DDM™ Platform is empowering institutions worldwide to implement high-performance decentralized liquid biopsy testing, ultimately advancing precision oncology. 

Learning Objectives 

1. Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction. 

2. Evaluate Performance and Real-World Validation – Gain insights into the internal verification study results and real-world data from six Privileged Access Program (PAP) sites, demonstrating high concordance between the decentralized and single-site versions of MSK-ACCESS®. 

3. Explore the Impact on Precision Oncology – Discover how the successful adoption of a decentralized liquid biopsy solution fosters community-driven insights, continuously improving variant calling algorithms and expanding access to high-quality genomic testing.